Dengue Vaccine Market Set to Soar: Breakthrough Innovations and Growing Global Demand Fuel Rapid Growth 2025 | Top Companies - Sanofi, Panacea Biotec, Biological

Market Overview:

The Dengue Vaccine Market is expected to grow at a CAGR of 10.4% during the forecast period 2024-2031. The Market is growing due to increasing global dengue cases and rising government initiatives to implement preventive immunization programs. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/dengue-vaccine-market?sz

The Dengue Vaccine Market involves the development, production, and commercialization of vaccines aimed at preventing dengue virus infections. It encompasses vaccines for all four dengue virus serotypes, targeting at-risk populations globally. Market growth is driven by increasing dengue prevalence, government immunization initiatives, rising healthcare awareness, and advancements in vaccine technology, including live-attenuated, recombinant, and DNA-based vaccines.

United States: Recent Developments of Dengue Vaccine Market

✅ October 2025: Merck & Co., Inc. initiated a Phase 3 trial (MOBILIZE-1) for its quadrivalent dengue vaccine candidate V181 targeting all four serotypes, aiming to strengthen global vaccine options beyond endemic populations.

✅ November 2025: The U.S. Centers for Disease Control and Prevention (CDC) continued to emphasize increased dengue risk and updated testing recommendations in the U.S., supporting growing public health awareness and vaccine uptake efforts.

✅ December 2025: The market size for dengue vaccines in the U.S. was estimated at around USD 751 million in 2025, with projections for strong growth driven by vaccination programs, traveler safety campaigns, and ongoing R&D advancements.

Europe: Recent Developments of Dengue Vaccine Market

✅ October 2025: European countries such as France and Spain incorporated dengue vaccination into public health plans for vulnerable groups, supported by traveler awareness campaigns emphasizing pre-travel immunization.

✅ November 2025: The European Union committed funding to studies on dengue prevention and mosquito control programs, advancing public health initiatives to curb the spread of dengue within the region.

✅ December 2025: The European Medicines Agency (EMA) expanded vaccine approvals including Qdenga, broadening vaccination options for travelers and residents in dengue risk areas, contributing to fastest market CAGR projections of approximately 17.9%.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/dengue-vaccine-market?sz

Regulatory Approvals & New Authorizations in 2025:

✅ Butantan‐DV (single‐dose dengue vaccine) - On 26 November 2025, the regulatory authority in Brazil, ANVISA, approved Butantan‐DV for use in individuals 12-59 years old. This marks the world's first single‐dose dengue vaccine to be authorized.

✅ The approval makes Butantan‐DV eligible for inclusion in Brazil's national immunization programme, with already more than 1 million doses reportedly manufactured and supply planned to expand substantially by 2026.

✅ QDENGA (TAK‐003, from Takeda) - On 3 November 2025, Takeda announced completion of its 7‐year pivotal Phase III TIDES trial, showing sustained protection against dengue infection and hospitalization over that period.

✅ Key results: two-dose regimen maintained efficacy across all four dengue serotypes for up to 7 years; after a booster dose, efficacy against hospitalization remained very high.

✅ According to Takeda, QDENGA is now the "longest‐studied dengue vaccine" with more than 60,000 participants in its clinical program.

Major Players:

Key companies in the Dengue Vaccine market include:

Sanofi
Panacea Biotec
Biological
E. Limited
GlaxoSmithKline plc
Merck & Co.
Takeda Pharmaceutical Company Ltd
Vabiotec
Panacea Biotec
Medigen Biologics.

Segments Covered in the Dengue Vaccine Market:

By Type: CYD-TDV, DENVax or TAK-003, TetraVax-DV, TDENV PIV, V180.

By End-user: Hospitals, Clinics, Vaccination Center, Others.

Regional Analysis for Dengue Vaccine Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=dengue-vaccine-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Dengue Vaccine market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Dengue Vaccine Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Dengue Vaccine market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Dengue Vaccine Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Dengue Vaccine market?

➠ Who are the global key manufacturers of the Dengue Vaccine Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Dengue Vaccine market opportunities and threats faced by the vendors in the global Dengue Vaccine Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Dengue Vaccine market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.